NCT00333021View on ClinicalTrials.gov

Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

May 31, 2006

Study Completion Date

February 28, 2007

Conditions
Venous Thromboembolism
Interventions
DRUG

Fondaparinux sodium

DRUG

GSK576428

Trial Locations (18)

737-0811

GSK Investigational Site, Hiroshima

060-0061

GSK Investigational Site, Hokkaido

060-8543

GSK Investigational Site, Hokkaido

073-0164

GSK Investigational Site, Hokkaido

655-0004

GSK Investigational Site, Hyōgo

300-0053

GSK Investigational Site, Ibaraki

760-0017

GSK Investigational Site, Kagawa

890-0061

GSK Investigational Site, Kagoshima

892-8580

GSK Investigational Site, Kagoshima

630-0227

GSK Investigational Site, Nara

540-0006

GSK Investigational Site, Osaka

560-0055

GSK Investigational Site, Osaka

565-0871

GSK Investigational Site, Osaka

589-8511

GSK Investigational Site, Osaka

590-0132

GSK Investigational Site, Osaka

598-0048

GSK Investigational Site, Osaka

351-0102

GSK Investigational Site, Saitama

152-0021

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00333021 - Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients | Biotech Hunter | Biotech Hunter